Celltran clinches £1m funding:
This article was originally published in Clinica
UK wound care therapy developer Celltran is accelerating the development and commercialisation of its core products after securing £1m ($2m) in additional funding. The Sheffield-based company said its Ulcodress plus (for treating static chronic wounds) and Cryoskin (for treating burns) products are poised to enter the market. It already has a revenue-generating product, Myskin, available in the UK, while Lyphoderm, a wound care product made from freeze-dried donor skin cells, is about to enter phase III trials. The financing round was led by Yorkshire Fund Managers and included contributions from all Celltran's existing shareholders including South Yorkshire Investment Fund, Innogetics, Biofusion, White Rose Technology Seedcore Fund and PUK Ventures.